Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054904 | 0.92 | PDE4B (0.57) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4053547 | 0.90 | PDE4B (0.56) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4050108 | 0.89 | PDE4B (0.63) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4054383 | 0.89 | PDE4B (0.54) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4049804 | 0.89 | PDE4B (0.54) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4052637 | 0.89 | PDE4B (0.54) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3036709 | 0.88 | PDE4B (0.71) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4052404 | 0.88 | PDE4B (0.55) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4053504 | 0.88 | PDE4B (0.53) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4050336 | 0.88 | PDE4B (0.53) | PDE4BTBXAS1ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-29 | — | — | US | claimed |
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE4B | PDE4B 3/4885TBXAS1 1019/4885ALDH1A1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.